In particular, lowering LDL levels pharmacologically in patients at risk for anaphylaxis may lower PAF-AH activity in these patients as well, inadvertently leading to an increased risk of severe or fatal anaphylaxis. Here, PLA2G7 is linked to anaphylaxis.